On the other hand, in syngeneic fully immunocompetent mice, there would be other mechanisms additionally employed by SOT101 which would contribute to ADCC of the therapeutic antibodies and anti-tumor efficacy such as activation of NKT cell, γδ T cells and stimulation of cytotoxic CD8+ T cells (12). This evidence concerns the gene CD8A and neoplasm.